AOD 9604: The GH Fragment Peptide for Fat Metabolism Research

**Disclaimer:** This article is provided for educational and research purposes only. AOD 9604 is not approved by the FDA for therapeutic use in the United States. Viking Labs does not sell AOD 9604. Nothing in this article constitutes medical advice. All references are to published research.

Introduction

The lipolytic (fat-mobilizing) effects of growth hormone (GH) have been recognized since the classical studies of Raben and Hollenberg in the 1950s and 1960s. However, the use of full-length recombinant human growth hormone (rhGH) for body composition modification carries significant limitations: GH is diabetogenic (promotes insulin resistance), stimulates IGF-1-mediated growth of tissues including potentially neoplastic ones, causes fluid retention, and requires careful dose titration to avoid adverse effects. The question of whether the lipolytic activity of GH could be separated from its growth-promoting and diabetogenic properties led to a systematic investigation of GH fragment peptides beginning in the 1990s.

AOD 9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone --- specifically, amino acids 177 through 191 of the 191-amino acid hGH sequence, with a tyrosine residue added at the N-terminus. This modified fragment, developed at Monash University in Melbourne, Australia, by a team led by Frank Ng and Gary Wittert, was designed to retain the lipolytic activity of full GH while lacking its effects on IGF-1 production, longitudinal growth, and glucose homeostasis.

Mechanism of Action

The mechanism through which AOD 9604 stimulates lipolysis has been the subject of considerable investigation, though it remains incompletely understood. What is established is that the peptide acts through a pathway that is distinct from the canonical GH receptor (GHR)/JAK2/STAT5 signaling cascade responsible for GH's growth-promoting and IGF-1-stimulating effects.

Heffernan et al. (2001) demonstrated in a series of in vitro studies using 3T3-L1 adipocytes and primary rat adipocytes that AOD 9604 stimulates lipolysis in a dose-dependent manner. The lipolytic activity was comparable in magnitude to that of full-length hGH but --- critically --- AOD 9604 did not stimulate IGF-1 release from hepatocytes or promote chondrocyte proliferation, confirming the dissociation of lipolytic from growth-promoting activities.

The lipolytic mechanism appears to involve enhancement of beta-3 adrenergic receptor-mediated signaling. Beta-3 adrenergic receptors are expressed primarily on adipocytes and, when activated, stimulate cyclic AMP (cAMP) production, protein kinase A (PKA) activation, and phosphorylation of hormone-sensitive lipase (HSL) and perilipin, leading to hydrolysis of stored triglycerides and release of free fatty acids and glycerol. Ng et al. proposed that the C-terminal domain of GH facilitates this pathway through interactions with a membrane-associated binding site that is distinct from the classical GHR.

AOD 9604 also appears to inhibit lipogenesis (new fat synthesis). Studies in obese Zucker rats demonstrated that chronic AOD 9604 treatment reduced the activity of key lipogenic enzymes, including fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), in adipose tissue. This dual action --- stimulating fat breakdown while inhibiting fat storage --- distinguishes AOD 9604 from agents that act only on one arm of the energy balance equation.

Importantly, AOD 9604 does not bind the growth hormone receptor with appreciable affinity. The fragment lacks the key residues in the GH molecule required for GHR dimerization and activation, which explains why it does not stimulate the JAK2/STAT5 pathway or induce IGF-1 production. This receptor-independent mechanism also suggests that AOD 9604 and full-length GH may exert their lipolytic effects through different molecular targets, though both converge on the same downstream lipase activation pathway.

Preclinical Evidence

The preclinical development of AOD 9604 was conducted primarily at Monash University using multiple animal models of obesity.

In genetically obese (ob/ob) mice, chronic AOD 9604 administration (over 18 days) produced significant reductions in body weight gain and adipose tissue mass compared to vehicle-treated controls. The weight loss was specific to adipose tissue; lean body mass was preserved, a finding consistent with the peptide's lack of anabolic activity. Notably, fasting blood glucose levels were not altered by AOD 9604 treatment, confirming the absence of the diabetogenic effect characteristic of full GH.

In diet-induced obese mice (fed a high-fat diet for 12 weeks to induce obesity resembling the human metabolic syndrome), AOD 9604 reduced body weight, improved insulin sensitivity, and decreased hepatic lipid accumulation. These effects were observed with both intraperitoneal injection and, remarkably, oral administration --- a finding that generated considerable excitement given that most peptides are degraded in the GI tract and lack oral bioavailability.

Oral efficacy was further explored in studies by Stier et al. (2004), who demonstrated that AOD 9604 administered orally in obese rats reduced body weight gain by approximately 50% compared to vehicle, with the effect primarily attributable to reduced adipose tissue accretion. The mechanism of oral activity remains unclear; it is possible that the peptide acts locally on gut-associated targets or that sufficient intact peptide crosses the intestinal barrier to achieve systemic concentrations.

Clinical Trials

AOD 9604 advanced through several clinical trials, with mixed results that illustrate the challenges of translating promising preclinical data into human therapeutics.

A Phase IIa study in obese adults evaluated oral AOD 9604 at 25, 50, and 200 micrograms daily over 12 weeks. The study reported trends toward greater weight loss but differences did not reach statistical significance. Safety data were reassuring: no significant adverse events, no effects on IGF-1, fasting glucose, insulin, or bone turnover markers, confirming in humans the dissociation of lipolytic from growth-promoting activities.

TGA Regulatory History

In Australia, AOD 9604 received a notable regulatory distinction. The Therapeutic Goods Administration (TGA) granted it Generally Recognized As Safe (GRAS) status for use as a food ingredient. This designation, while not equivalent to therapeutic approval, was based on the extensive safety data generated during the clinical program and reflects the peptide's favorable tolerability profile. The GRAS status has led to the inclusion of AOD 9604 in certain nutraceutical and food supplement products in some jurisdictions, though the evidence supporting its efficacy in this context is limited.

Comparison to Full-Length Growth Hormone

The fundamental value proposition of AOD 9604 is the dissociation of GH's lipolytic effects from its growth, diabetogenic, and fluid-retention effects. This comparison is worth examining in detail.

Full-length hGH (191 amino acids, ~22 kDa) activates the GH receptor, leading to JAK2 phosphorylation, STAT5 activation, and transcription of target genes including IGF-1. IGF-1 mediates the majority of GH's anabolic and growth-promoting effects, including longitudinal bone growth, increased lean mass, and organ growth. GH also directly stimulates lipolysis, hepatic gluconeogenesis (contributing to insulin resistance), and sodium/water retention.

AOD 9604 (16 amino acids with an N-terminal tyrosine, ~1.8 kDa) retains only the lipolytic arm of this pharmacology. It does not raise IGF-1, does not promote tissue growth, does not impair glucose homeostasis, and does not cause fluid retention. However, this selectivity comes at the cost of reduced potency: the fragment is less potent than full GH in lipolysis assays, requiring higher molar concentrations to achieve equivalent effects. The clinical consequence is that while AOD 9604 is safer than GH, its efficacy as a weight loss agent in the clinical setting has been more modest than the preclinical data suggested.

Current Status and Research Directions

Following the inconclusive Phase IIa clinical results, the original commercial development program for AOD 9604 as an oral obesity therapeutic was deprioritized. However, research interest in the peptide continues in several areas.

Musculoskeletal research has explored AOD 9604 for cartilage repair, based on findings that the peptide promotes proteoglycan synthesis in chondrocytes. A formulation combining AOD 9604 with hyaluronic acid has been investigated for intra-articular injection in osteoarthritis, with preliminary data suggesting improvements in cartilage integrity markers. This represents a mechanistically distinct application from the peptide's originally intended metabolic use.

The peptide also continues to be studied in the context of metabolic syndrome, where its effects on hepatic lipid metabolism and insulin sensitivity --- observed in preclinical models but not fully evaluated in clinical trials --- may offer therapeutic relevance beyond simple weight loss.

Summary

AOD 9604 represents a rational approach to separating the desirable lipolytic effects of growth hormone from its undesirable growth-promoting and diabetogenic properties. The peptide stimulates fat metabolism through a beta-3 adrenergic receptor-associated pathway independent of the classical GH receptor. While preclinical data were robust, clinical efficacy in human obesity has been modest. The peptide's favorable safety profile and unique mechanism continue to sustain research interest, particularly in metabolic and musculoskeletal applications.

*This article is provided for informational and research purposes only. Viking Labs does not sell AOD 9604. Nothing in this article should be construed as medical advice.*